ReviewFluids and barriers of the CNS2026
Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain.
Review in Fluids and barriers of the CNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- RVG29-functionalized nanocarriers for brain-targeted therapy of neurodegenerative diseases: mechanisms, therapeutic advances, and translational perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Advances in Nanomedicine for Brain Tumors: Overcoming Biological Barriers, Targeting Strategies, and Future Directions.Current neurology and neuroscience reports · 2026Review
- TAMing the tumor: targeting immune inhibitory receptors on tumor-associated macrophages in pediatric brain tumors - an emerging immunotherapy strategy.Journal for immunotherapy of cancer · 2026Review
- TREM2 in glioma: Reprogramming the immune microenvironment from mechanistic understanding to clinical translation (Review).Molecular medicine reports · 2026Review
- Systematic Design and Evaluation of Nasal Drug Delivery for Central Nervous System Disease from Experimental to Clinical Application.Pharmaceutics · 2026Review
- ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Cancer chemotherapy and pharmacology · 2026Review
- CAR T-cells for the treatment of CNS malignancies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unique anatomical and physiological features of the blood-brain barrier (BBB), while essential for maintenance of normal brain health, present significant challenges in development of effective therapies for neurological disorders from a drug delivery perspective. This is particularly the case for biotherapeutics such as monoclonal antibodies, which have a restricted brain distribution following systemic administration. While the BBB is often presumed to be leaky in tumors within the brain, it is important to recognize that the degree of compromise is highly variable with certain regions such as micro-tumors and infiltrative margins of larger tumors having a functional and intact BBB. Given this, limited delivery of therapeutic agents across the BBB poses a critical challenge that needs to be overcome to improve treatment outcomes in patients diagnosed with tumors in the brain. Here, we review various considerations relevant to distribution of biologics to tumors in the brain, both primary brain tumors and secondary metastases to the brain. We discuss the various strategies being explored to enhance the delivery of biotherapeutics across the BBB and outline the associated limitations. We also highlight the cross-talk between the drug delivery strategies for neurological disorders and neuro-oncology indications as an important area of research that should be encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.